Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have previously shown that the interleukin 10 (IL-10)/-592*A allele of the recipient is associated with less severe acute
graft-versus-host disease
(
GVHD
) and a lower risk of nonrelapse mortality after hematopoietic cell transplantation (HCT) from an HLA-identical sibling. In the present study, we examined variation in the IL-10 receptor beta gene as a further test of the hypothesis that the IL-10 pathway regulates the risk of acute
GVHD
. A single nucleotide polymorphism (A/G) at cDNA position 238 of the IL-10 receptor beta gene (
IL10RB
/c238) was genotyped in 953 HC transplant recipients and their HLA-identical sibling donors. IL-10/-592 and
IL10RB
/c238 genotypes were tested for association with
GVHD
by multivariable analysis. The IL-10/-592*A allele of the recipient and
IL10RB
/c238*G allele of the donor were significantly associated with a lower risk of grades III-IV acute
GVHD
(trend P < .001 and P = .02, respectively). The donor
IL10RB
/c238*G allele provided protection among patients with the IL-10/-592 A/C or A/A genotypes but not among patients with the high-risk IL-10/-592 C/C genotype. These data suggest an interaction of the patient IL-10/-592 and donor
IL10RB
/c238 genotypes on risk of
GVHD
, further supporting the hypothesis that the IL-10 pathway plays an important role in controlling the severity of acute
GVHD
.
...
PMID:Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. 1610 75